What question did this study set out to answer?

This research aims to evaluate the early effects of vedolizumab on transmural healing in patients with Crohn’s disease.

P1007Evaluation of transmural healing in patients with moderately to severely active Crohn’s disease shows early efficacy of vedolizumab: VECTORS week 14 interim analysis

View Full Paper

Ask AI

Bookmark

Authors

Interim analysis shows early efficacy of vedolizumab achieving transmural healing in Crohn’s disease, suggesting potential for improved outcomes.

This research aims to evaluate the early effects of vedolizumab on transmural healing in patients with Crohn’s disease.
48-week treat-to-target algorithm featuring intravenous vedolizumab (VDZ) 300 mg
Participants are randomized into two groups with different treatment targets
Assessment of bowel wall thickness and clinical biomarkers at specified weeks
54 participants were randomized; 76% reached 14 weeks of treatment
Group 1 showed a 42% improvement in bowel ultrasound scores
Clinical measures indicated significant reductions in CD activity and inflammation biomarkers

Jairath et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Interim analysis shows early efficacy of vedolizumab achieving transmural healing in Crohn’s disease, suggesting potential for improved outcomes.